Don’t miss the latest developments in business and finance.

Glenmark Launches Novel, Globally-Researched Anti-diabetes Drug Remogliflozin in India

Image
Press Trust of India MUMBAI
Last Updated : Apr 30 2019 | 12:15 PM IST

/ -- Remogliflozin is an innovative, patent-protected sodium glucose co-transporter-2 (SGLT2) inhibitor indicated in treatment of type-2 diabetes mellitus in adults SGLT2 inhibitors are cutting-edge, globally-accepted latest class of oral anti-diabetes drugs that provide glycemic control, induce weight loss and reduce cardiovascular risks
(Logo: https://bsmedia.business-standard.commma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg )
India is estimated to have around 72 million adults living with diabetes, according to the International Diabetes Federation's Diabetes Atlas 2017.1
About Glenmark Pharmaceuticals
Reference:

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Apr 30 2019 | 12:15 PM IST

Next Story